| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 14th August 2020 | Earl W Brien | 150,000 | Exercise of derivative | $0.26 | $39,000.00 |
| 7th August 2020 | Steven A Kriegsman | 3,000,000 | Exercise of derivative | $0.26 | $780,000.00 |
| 7th August 2020 | Steven A Kriegsman | 1,164,179 | Payment by withholding | $0.67 | $779,999.93 |
| 7th August 2020 | Louis Ignarro | 700,000 | Exercise of derivative | $0.26 | $182,000.00 |
| 7th August 2020 | Louis Ignarro | 271,642 | Payment by withholding | $0.67 | $182,000.14 |
| 7th August 2020 | Joel K Caldwell | 450,000 | Exercise of derivative | $0.26 | $117,000.00 |
| 7th August 2020 | Joel K Caldwell | 174,627 | Payment by withholding | $0.67 | $117,000.09 |
Cyt Rx Corporation
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
CytRx Corp. is a biopharmaceutical research and development company. It focuses on developing novel anti-cancer drug candidates. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Ticker: CYTR
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 799698
Employees: 6
Exchange: US OTC
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
